Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

NCT00864175 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

68

Enrollment

INDUSTRY

Sponsor class

Stopped Incyte suspended development of the compound.

Conditions

Breast Cancer

Interventions

DRUG: INCB007839
DRUG: INCB007839
DRUG: INCB007839
DRUG: INCB007839
DRUG: trastuzumab
DRUG: Docetaxel

Sponsor

Incyte Corporation